Madrigal Pharmaceuticals
Madrigal Pharmaceuticals
MDGL
NASDAQ
321.00
USD
-0.63%
About
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH.
NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 189.6K |
| Three Month Average Volume | 8.0M |
| High Low | |
| Fifty-Two Week High | 299.98 USD |
| Fifty-Two Week Low | 119.7604 USD |
| Fifty-Two Week High Date | 15 Mar 2024 |
| Fifty-Two Week Low Date | 27 Oct 2023 |
| Price and Volume | |
| Current Price | 247.13 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -15.05% |
| Thirteen Week Relative Price Change | -2.23% |
| Twenty-Six Week Relative Price Change | -10.68% |
| Fifty-Two Week Relative Price Change | 9.57% |
| Year-to-Date Relative Price Change | -9.81% |
| Price Change | |
| One Day Price Change | -0.64% |
| Thirteen Week Price Change | 4.65% |
| Twenty-Six Week Price Change | -1.79% |
| Five Day Price Change | -2.22% |
| Fifty-Two Week Price Change | 37.29% |
| Year-to-Date Price Change | 6.81% |
| Month-to-Date Price Change | -13.18% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 20.39367 USD |
| Book Value Per Share (Most Recent Quarter) | 39.497 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 20.39367 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 39.27074 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -26.59386 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.73509 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -19.99329 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -25.49536 USD |
| Normalized (Last Fiscal Year) | -19.99329 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -19.99329 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -25.49536 USD |
| Including Extraordinary Items (Last Fiscal Year) | -19.99329 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -25.49536 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 31.90527 USD |
| Cash Per Share (Most Recent Quarter) | 48.74427 USD |
| Cash Flow Per Share (Last Fiscal Year) | -19.96509 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -25.59765 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -22.89011 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -3,114 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -3,487.13% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | 95.66% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -3,622.65% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -3,487.13% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -8.01% |
| Tangible Book Value (5 Year) | -3.20% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 132.01% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -51.54% |
| EPS Change (Trailing Twelve Months) | -36.75% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 13 |
| Price to Tangible Book (Most Recent Quarter) | 6 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -941,187,000 |
| Net Debt (Last Fiscal Year) | -518,651,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | 367 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 12 |
| Price to Book (Most Recent Quarter) | 6 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 28 |
| Long Term Debt to Equity (Most Recent Quarter) | 14 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | 9 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 9 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -325,709,000 |
| Free Cash Flow (Trailing Twelve Months) | -455,818,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 28 |
| Total Debt to Equity (Most Recent Quarter) | 14 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -74.49% |
| Return on Assets (Trailing Twelve Months) | -72.80% |
| Return on Assets (5 Year) | -62.09% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -123.98% |
| Return on Equity (Trailing Twelve Months) | -106.27% |
| Return on Equity (5 Year) | -80.27% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -97.21% |
| Return on Investment (Trailing Twelve Months) | -86.71% |
| Return on Investment (5 Year) | -74.81% |